Dry powder composition for peroral administration
There is provided a pharmaceutical dosage form that is suitable for peroral administration to the gastrointestinal tract, which dosage form comprises a pharmaceutical composition in the form of a particulate mixture comprising solid particles of N-butyloxycarbonyl-3-(4-imidazol-1-ylmethylphenyl)-5-iso-butylthiophene-2-sulfonamide (C21), or a pharmaceutically-acceptable salt thereof, admixed with a blend of carrier particles with weight- and/or a volume-based mean diameter, and/or a structural/particle density, that is/are similar to the weight- and/or volume-based mean diameter, and/or the structural/particle density, of the solid particles of C21, and a glidant, which composition is contained within a capsule that is suitable for such peroral administration. Preferred carrier particles have a weight- and/or a volume-based mean diameter that is less than about 100 μm. Preferred carrier particle materials include mannitol. Preferred glidants comprise colloidal silica. Such dosage forms find utility in the treatment of lung diseases, such as idiopathic pulmonary fibrosis, sarcoidosis and respiratory virus-induced tissue damage.
1. A pharmaceutical dosage form that is suitable for peroral administration to the gastrointestinal tract, which dosage form comprises a pharmaceutical composition in the form of a particulate mixture comprising:
(a) solid particles of N-butyloxycarbonyl-3-(4-imidazol-1-ylmethylphenyl)-5-iso-butylthiophene-2-sulfonamide sodium salt thereof, admixed with
(b) a blend of:
(i) carrier particles having a weight-based mean diameter and/or a volume-based mean diameter that is less than about 100 μm, and a structural/particle density that is within about ±20% of a structural/particle density of the solid particles of N-butyloxycarbonyl-3-(4-imidazol-1-ylmethylphenyl)-5-iso-butylthiophene-2-sulfonamide sodium salt, and
(ii) a glidant,
which composition is contained within a capsule that is suitable for such peroral administration.
2. The dosage form as claimed in claim 1 , wherein the capsule is a hard-shell, two-piece capsule.
3. The dosage form as claimed in claim 1 , wherein the capsule is made from hydroxypropyl methylcellulose.
4. The dosage form as claimed in claim 1 wherein the carrier particle mean diameter is between about 20 μm and about 60 μm.
5. The dosage form as claimed in claim 1 wherein the carrier particle material comprises mannitol.
6. The dosage form as claimed in claim 1 wherein the glidant comprises a colloidal silica.
7. The dosage form as claimed in claim 1 , wherein smaller particles of the glidant material coat the carrier particles.
8. The dosage form as claimed in claim 1 , which further comprises a lubricant.
9. The dosage form as claimed in claim 8 , wherein the lubricant is magnesium stearate.
10. The dosage form as claimed in claim 1 that is essentially water-free.
11. A process for the production of a dosage form as defined in claim 1 , which process comprises:
(a) mixing together the carrier particles and the glidant;
(b) mixing the blend from step (a) with the solid particles of N-butyloxycarbonyl-3-(4-imidazol-1-ylmethyl-phenyl)-5-iso-butylthiophene-2-sulfonamide sodium; and
(c) loading the mixture from step (b) into a capsule that is suitable for peroral administration.
12. The process as claimed in claim 11 , wherein:
(i) prior to step (c), a lubricant is mixed together with the mixture from step (b); and/or
(ii) the mixture from step (a), and/or step (b) (before and/or after adding the lubricant as appropriate) is passed through a sieve at least once in order to break up any agglomerates that are formed during the blending process.
13. The process as claimed in claim 12 , wherein at least one of the sieving steps comprises passing through a sieve that is of a size of about 800 μm.
14. A dosage form obtainable by the process as defined in claim 11 .
15. A method of treatment of an interstitial lung disease, which method comprises the administration of the dosage form as defined in claim 1 to a patient in need of such treatment.
16. The method of treatment as claimed in claim 15 , wherein the interstitial lung disease is idiopathic pulmonary fibrosis.
17. The method of treatment as claimed in claim 15 , wherein the interstitial lung disease is sarcoidosis.
18. The method of treatment as claimed in claim 15 , wherein the treatment includes prevention of morbidity and/or mortality in the relevant condition.
19. The method of treatment as claimed in claim 15 , wherein the composition is administered by the peroral route.
20. A pharmaceutical dosage form that is suitable for peroral administration to the gastrointestinal tract, which dosage form is a hard-shell, two-piece capsule containing a pharmaceutical composition in the form of a particulate mixture comprising:
(a) solid particles of N-butyloxycarbonyl-3-(4-imidazol-1-ylmethylphenyl)-5-iso-butylthiophene-2-sulfonamide sodium, admixed with
(b) a blend of:
(i) carrier particles comprising mannitol having a weight-based mean diameter and/or a volume-based mean diameter that is less than about 100 μm, and a structural/particle density that is within about ±20% of a structural/particle density of the solid particles of N-butyloxycarbonyl-3-(4-imidazol-1-ylmethylphenyl)-5-iso-butylthiophene-2-sulfonamide sodium salt, which carrier particles are coated by
(ii) smaller particles of a glidant comprising colloidal silica,
which composition is contained within the capsule and is suitable for such peroral administration.
21. The dosage form as claimed in claim 1 , wherein the carrier particles have a structural/particle density that is within about ±10% of the structural/particle density of the solid particles of N-butyloxycarbonyl-3-(4-imidazol-1-ylmethylphenyl)-5-iso-butylthiophene-2-sulfonamide sodium salt.
22. The dosage as claimed in claim 20 , wherein the carrier particles have a structural/particle density that is within about ±10% of the structural/particle density of the solid particles of N-butyloxycarbonyl-3-(4-imidazol-1-ylmethylphenyl)-5-iso-butylthiophene-2-sulfonamide sodium salt.
23. The dosage form as claimed in claim 1 , wherein the primary solid particles of N-butyloxycarbonyl-3-(4-imidazol-1-ylmethylphenyl)-5-iso-butylthiophene-2-sulfonamide sodium salt have a weight- and/or a volume-based mean diameter of no more than about 50 μm.
24. The dosage form as claimed in claim 1 , wherein the primary solid particles of N-butyloxycarbonyl-3-(4-imidazol-1-ylmethylphenyl)-5-iso-butylthiophene-2-sulfonamide sodium salt have a weight- and/or a volume-based mean diameter of no more than about 20 μm.
25. The dosage form as claimed in claim 1 , wherein the primary solid particles of N-butyloxycarbonyl-3-(4-imidazol-1-ylmethylphenyl)-5-iso-butylthiophene-2-sulfonamide sodium salt have a weight- and/or a volume-based mean diameter of no more than about 10 μm.
26. The dosage form as claimed in claim 20 , wherein the primary solid particles of N-butyloxycarbonyl-3-(4-imidazol-1-ylmethylphenyl)-5-iso-butylthiophene-2-sulfonamide sodium salt have a weight- and/or a volume-based mean diameter of no more than about 50 μm.
27. The dosage form as claimed in claim 20 , wherein the primary solid particles of N-butyloxycarbonyl-3-(4-imidazol-1-ylmethylphenyl)-5-iso-butylthiophene-2-sulfonamide sodium salt have a weight- and/or a volume-based mean diameter of no more than about 20 μm.
28. The dosage form as claimed in claim 20 , wherein the primary solid particles of N-butyloxycarbonyl-3-(4-imidazol-1-ylmethylphenyl)-5-iso-butylthiophene-2-sulfonamide sodium salt have a weight- and/or a volume-based mean diameter of no more than about 10 μm.